Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.

Festuccia, Claudio

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. [electronic resource] - Endocrine-related cancer Jun 2009 - 401-13 p. digital

Publication Type: Journal Article

1351-0088

10.1677/ERC-08-0130 doi


Animals
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Apoptosis--drug effects
Azacitidine--therapeutic use
Blotting, Western
Caspase 3--metabolism
Cell Proliferation--drug effects
Cisplatin--administration & dosage
Cyclin D1--metabolism
Cyclin-Dependent Kinase Inhibitor p16--metabolism
Cyclin-Dependent Kinase Inhibitor p21--metabolism
Cyclin-Dependent Kinase Inhibitor p27--metabolism
Disease Models, Animal
Docetaxel
Drug Synergism
Drug Therapy, Combination
Flow Cytometry
Humans
Male
Mice
Mice, Nude
Prostatic Neoplasms--drug therapy
Proto-Oncogene Proteins c-bcl-2--metabolism
Signal Transduction
Taxoids--administration & dosage
Xenograft Model Antitumor Assays
bcl-2 Homologous Antagonist-Killer Protein--metabolism
bcl-2-Associated X Protein--metabolism